Lit­tle vTv Ther­a­peu­tics adds an­oth­er round of bad da­ta on Alzheimer's drug, but they still love their chances

In Alzheimer’s, fail­ure seems to spring eter­nal, but that doesn’t mean you can’t find some­thing to sell to in­vestors.

We al­ready know that vTv Ther­a­peu­tics $VTVT racked up one of the lat­est fail­ures in Alzheimer’s re­search af­ter its lead drug — azeli­ragon — failed the first part of a piv­otal study. Now it is con­ced­ing that Part B was al­so a fail­ure on both end­points, but it’s ask­ing in­vestors to keep the faith as they ex­tract signs of suc­cess they hope to use to get back in­to the clin­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.